El Miami Herald da como aprobado a Yondelis en EEUU para Cáncer de Ovario ... sin duda estan en un error ... hablando en presente ... :
THE FDA OK
Although developed in the United States, Yondelis has yet to receive FDA approval for treatment of sarcoma. It is, however, approved for women with relapsed ovarian cancer.
David Newman, chief of the natural products branch at the National Cancer Institute, said to expect more drugs from the sea in the future.
The reason: small marine life with no physical defenses have developed chemical compounds not found on land to help them fend off ocean predators.
``A sponge can't swim. Has no teeth,'' Newman said. ``What does he use for defense? Chemistry. Chemical warfare is a live and well on a coral reef.''
In the pharmaceutical pipeline, many isolated chemical compounds extracted from marine organisms are being researched and tested on rodents and humans.
03 octubre 2010
Potent cancer fighter lies in Keys algae beds . II Parte .
Recuerdos aquellos de cuando SeaPharm Inc ... siempre con el tiempo se llega a ver el bosque .
...
As for Yondelis, the seeds of its development were sewn back in 1967, when researchers at the University of Miami found that a compound in sea squirts stopped the growth of cancer tumors in nine of 10 mice.
But the discovery had little practical application until scientists could ``crack the structure'' of the compound. Amy Wright, a research professor at FAU's Harbor Branch Oceanographic Institute, was involved in doing just that when she was a researcher at a little company called Seapharm Inc. Years later, Yondelis was the result.
``The ocean is full of things to investigate,'' Luesch said. ``We have only scratched
the surface . . . The opportunities for marine drug discovery are tremendous. I'm certainly a believer.''
...
As for Yondelis, the seeds of its development were sewn back in 1967, when researchers at the University of Miami found that a compound in sea squirts stopped the growth of cancer tumors in nine of 10 mice.
But the discovery had little practical application until scientists could ``crack the structure'' of the compound. Amy Wright, a research professor at FAU's Harbor Branch Oceanographic Institute, was involved in doing just that when she was a researcher at a little company called Seapharm Inc. Years later, Yondelis was the result.
``The ocean is full of things to investigate,'' Luesch said. ``We have only scratched
the surface . . . The opportunities for marine drug discovery are tremendous. I'm certainly a believer.''
Suscribirse a:
Entradas (Atom)